Whitehawk Therapeutics, Inc.
NCM: WHWKLive Quote
About Whitehawk Therapeutics, Inc.
Healthcare
Biotechnology
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
📊 Fundamental Analysis
Whitehawk Therapeutics, Inc. demonstrates a profit margin of -288.3%, which is below the sector average, suggesting competitive pressure.
The company recently reported -100.0% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -21.8%, which indicates that capital utilization is currently under pressure.
At a current price of $3.39, WHWK currently sits at the 65th percentile of its 52-week range (Range: $1.39 - $4.48).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$253.86M
Trailing P/E
--
Forward P/E
-2.83
Beta (5Y)
0.62
52W High
$4.48
52W Low
$1.39
Avg Volume
160K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App